News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Hilary C. Kelly, MPH

Advertisement

Articles by Hilary C. Kelly, MPH

Four Fungal Horsemen: Emerging Trends in Fungal Disease Epidemiology

ByHilary C. Kelly, MPH,Michael B. Henry, MD,MS Candidate,Brendan R. Jackson, MD, MPH,Karlyn D. Beer, PhD, MS
April 9th 2019

New public health perspectives on aspergillosis, sporotrichosis, histoplasmosis, and coccidioidomycosis.

Advertisement

Latest Updated Articles

  • Four Fungal Horsemen: Emerging Trends in Fungal Disease Epidemiology
    Four Fungal Horsemen: Emerging Trends in Fungal Disease Epidemiology

    Published: April 9th 2019 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients

2

Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Post-Antibiotic Era

3

Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP

4

One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us